focus -WSS

focus

author：hotspot 2025-09-07 06:44:50 - browse：99

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Dozens dead from Maui wildfires: What we know about the victims

explore

hotspot

WSS

Humana sues Biden admin over Medicare Advantage audit rule

Covid hospitalizations on the rise, Humana says

Why Novartis is changing the name of its research labs

Why Novartis is changing the name of its research labs

Maui wildfire now ranks as the fifth

Biden administration begins canceling student loan debt for 804,000 borrowers

knowledge

focus

leisure time

Cancer drug shortages should be causing more outrage

Montana youths win climate lawsuit against state for promoting fossil fuels

Jerome Adams on the need for new antivirals for Covid

Why Novartis is changing the name of its research labs

Wildfire smoke exposes gaps in outdoor worker protections

Biogen’s boardroom scandal saddles CEO with first crisis

State Dept. review finds Biden bears some blame for Afghanistan failures

Biogen’s boardroom scandal saddles CEO with first crisis

Medical records are filled with copy

Schizophrenia gene found to be linked to cells' energy dysfunction

hotspot

Indictment alleges Trump's ex

House transparency, PBM reform bill gains bipartisan support

Snackable artificial intelligence, expert AI, and the pharma industry

Mark Cuban is blaming the wrong people for high drug costs

Crinetics acromegaly drug succeeds in late

Trump surgeon general acknowledges mistakes during Covid

explore

hotspot

focus

hotspot